"This is the best of times for big data, and biology is at the forefront; With the brightest minds and biggest hearts to collaborate with, Genentech is an exciting place to be for a bioinformatics scientist like me, translating data into therapeutics for patients."
I got my PhD in Pathology from Univ. of Pittsburgh studying role of N-glycosylation in MHC class I biosynthesis. Towards the end of my PhD years I got bitten by the computer bug working on sequence analysis and pattern recognition to identify antigenic peptides presented by MHC class I molecules. After a postdoc at Columbia Univ. on small GTPases in phagocytosis, I joined Celera Genomics in 1998 and worked on drosophila, human and mouse genomes. While at Celera I also obtained a MS in Computer Sciences majoring in software engineering and bioinformatics from Johns Hopkins Univ.
In 2003 I joined Schering Plough. I provided bioinformatics support across various therapeutic areas and was involved in using bioinformatics approaches to find the drug target for a cholesterol absorption inhibitor post-approval. After the Merck merger, I became the bioinformatics/biomarker representative for the anti-PD1 (known as MK-3475 then) clinical trial team when it first went into patients in 2011. I also worked at Regeneron prior to joining Genentech, leading their Molecular Profiling and Bioinformatics effort supporting Oncology across the pipeline including discovery, dev sci, translational and clinical.
I joined Genentech in 2014 as a Sr. Scientist (bioinformatics) in Antibody Engineering. My group builds computational tools and pipelines, and performs data analysis to support Antibody Engineering. We also have joint appointments with the Bioinformatics & Computational Biology group, collaborating with B&CB colleagues revamping software infrastructure that supports Protein Sciences.
My group and I support Antibody Engineering and Protein Sciences in two areas:
(1) Apply innovative computational and bioinformatics approaches to advance antibody discovery and engineering. We develop algorithms, build computational tools and pipelines, and performs data analysis with an emphasis on antibody repertoire and next-generation sequencing.
(2) Revamp software infrastructure supporting Protein Sciences. I am the Business Lead for TaPIR, our new large molecule registration system, and also ProSE, the Protein Sciences Experiments system, capturing data from screening and characterization assays, and providing integrated data visualization and analysis to advance drug targets and support scientific research.